Scarica l'app Stockscreener
5.24
2.24%
-0.12
Precedente Chiudi:
$5.36
Aprire:
$5.36
Volume 24 ore:
340.77K
Relative Volume:
1.11
Capitalizzazione di mercato:
$363.49M
Reddito:
$28.31M
Utile/perdita netta:
$-250.99M
Rapporto P/E:
-1.4449
EPS:
-3.6266
Flusso di cassa netto:
$-242.07M
1 W Prestazione:
-7.42%
1M Prestazione:
-19.26%
6M Prestazione:
-28.71%
1 anno Prestazione:
-58.05%
Intervallo 1D:
$5.21
$5.54
Intervallo di 1 settimana:
$5.18
$5.95
Portata 52W:
$5.18
$13.11
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Nome
Bicycle Therapeutics Plc Adr
Settore
Industria
Telefono
011441223261503
Indirizzo
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
5.24 | 371.81M | 28.31M | -250.99M | -242.07M | -3.6266 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Hold |
| 2025-10-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | Iniziato | Stephens | Equal-Weight |
| 2024-09-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | Iniziato | Cowen | Outperform |
| 2022-07-28 | Iniziato | Barclays | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-04-13 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-02-14 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | SVB Leerink | Outperform |
| 2021-12-09 | Iniziato | Needham | Buy |
| 2021-09-30 | Iniziato | B. Riley Securities | Buy |
| 2021-04-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-12 | Iniziato | Oppenheimer | Outperform |
| 2020-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-09-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-06-17 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-17 | Iniziato | Goldman | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
| 2019-06-17 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Bicycle Therapeutics Plc Adr Borsa (BCYC) Ultime notizie
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Principal Financial Group Inc. Grows Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6%Time to Sell? - MarketBeat
Bicycle Therapeutics announces leadership changes for next phase By Investing.com - Investing.com South Africa
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com South Africa
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 - ChartMill
Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $70,210.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Operating cash flow per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView — Track All Markets
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-12-28 | Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Investors to Connect - ACCESS Newswire
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-24 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Connect - ACCESS Newswire
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - WV News
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages - Defense World
45,950 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Purchased by Dynamic Technology Lab Private Ltd - MarketBeat
Jefferies Financial Group Inc. Boosts Stock Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Coverage Initiated by Analysts at Truist Financial - Defense World
Total revenue of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Preferred dividends of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Truist Securities initiates coverage on Bicycle Therapeutics stock with Hold rating - Investing.com UK
Investigation Alert: Bicycle Therapeutics plc (BCYC) Under ScrutinyContact Levi & Korsinsky for Details - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - MarketScreener
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
A new trading data show Bicycle Therapeutics Plc ADR (BCYC) is showing positive returns. - setenews.com
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 8.8% Following Analyst Downgrade - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 8.8% After Analyst Downgrade - Defense World
Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat
EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat
Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa
Bicycle Therapeutics Plc Adr Azioni (BCYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):